Lexaria Bioscience to Attend BIO International Convention as Part of Expanded Business Development Push

Lexaria Bioscience Corp. (NASDAQ: LEXX) announced it will attend the BIO International Convention from June 22-25 in San Diego, California, as part of a broader business development program that has already shown positive results. The company, which specializes in oral drug delivery platforms, credits last year’s BIO convention as a catalyst for its significantly expanded business development efforts.

“We are experiencing record-high levels of business development and collaboration interest in our DehydraTECH platform, even before the upcoming BIO conference,” said Richard Christopher, CEO of Lexaria Bioscience. “New business relationships require intense energy and scientific evaluation from both prospective partners to discover the best fit possible. We are working tirelessly in this regard with the intent of generating positive developments that we can publicly discuss.”

BIO is the largest convention of its kind, with over 20,000 attendees expected from the global pharmaceutical and biotechnology industries, as well as investors and finance professionals. The conference focuses on intra-industry collaborations, with over 66,000 partnering meetings held at the 2025 event. Lexaria has already begun reserving meetings and expects to be fully booked given strong industry interest in its DehydraTECH platform.

The attendance at BIO is part of a multi-faceted business development program that Lexaria launched to inform prospective partners about DehydraTECH’s benefits. Although confidential discussions cannot be publicly disclosed, the program has already generated collaborative and potential business partnering talks with a range of companies, from smaller biotech developers to global pharmaceutical giants.

Lexaria’s business development program has developed several ongoing discussions and continues to generate early-stage leads. The company intends to evaluate each potential relationship thoroughly and pursue only those in the best interests of its shareholders. Additional information will be provided when appropriate.

DehydraTECH is Lexaria’s patented drug delivery formulation and processing platform that improves oral drug absorption. The platform has shown the ability to increase bio-absorption, reduce side effects, and deliver drugs more effectively across the blood-brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. For more information, visit www.lexariabioscience.com.

The company cautions that forward-looking statements in this release involve risks and uncertainties, and actual results may differ materially. Factors include market conditions, government regulation, competition, scientific discovery, and the company’s ability to maintain collaborations. No statement has been evaluated by the FDA, and Lexaria-associated products are not intended to diagnose, treat, cure, or prevent any disease.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Lexaria Bioscience to Attend BIO International Convention as Part of Expanded Business Development Push.

The post Lexaria Bioscience to Attend BIO International Convention as Part of Expanded Business Development Push appeared first on citybuzz.